Phuturdex › Diseases › Peripheral primitive neuroectodermal tumor
Drugs in development · updated 30 October 2026
Peripheral primitive neuroectodermal tumor: drugs in development
As of 30 October 2026 there are 10 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for peripheral primitive neuroectodermal tumor. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Tipifarnib | II | 2 | NCT04284774 |
| Ulixertinib | II | 2 | NCT03698994 |
| SamotolisibLY3023414 | II | 1 | NCT03155620 |
| 177Lu-DOTATOCLutetium Lu 177-Edotreotide | I | 1 | NCT06441331 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| EnsartinibX-396, Ensatinib | II | 2 | NCT03213652 |
| ErdafitinibBalversa® | II | 2 | NCT03210714 |
| IvosidenibAG-120, Tibsovo® | II | 2 | NCT03155620 |
| LarotrectinibBAY2757556, Vitrakvi® | II | 2 | NCT03155620 |
| SelpercatinibLOXO-292, Retevmo® | II | 2 | NCT04320888 |
| IrinotecanOnivyde, CPT-11 | I–II | 1 | NCT04901702 |
| OlaparibAZD2281, Lynparza® | II | 1 | NCT03155620 |
| PalbociclibPabociclib, Palbocicilib | II | 1 | NCT03155620 |
| SelumetinibAZD6244, Koselugo® | II | 1 | NCT03155620 |
| TalazoparibTalzenna® | I–II | 1 | NCT04901702 |
| TazemetostatTazverik® | II | 1 | NCT03155620 |
| TemozolomideTemodal, Temodar | I–II | 1 | NCT04901702 |
| VemurafenibZelboraf® | II | 1 | NCT03155620 |
Sorted by most advanced phase and number of active trials.
All 17 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Neuroblastoma 95 drugs
- Osteosarcoma 101 drugs
- Ewing sarcoma 82 drugs
- Rhabdomyosarcoma 68 drugs
- Sarcoma 204 drugs
- Wilms Tumor 37 drugs
- Rhabdoid tumor 52 drugs
- Medulloblastoma 77 drugs
- Hepatoblastoma 41 drugs
- Ganglioneuroblastoma 20 drugs
- Synovial sarcoma 33 drugs
- Neoplasm 671 drugs
Broader categories
- Glandular and epithelial neoplasm 12 drugs
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Nerve tissue neoplasm 4 drugs
- Neuroepithelial neoplasm 4 drugs
- Primitive neuroectodermal tumor 31 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018241 “Neuroectodermal Tumors, Primitive, Peripheral”.